• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

29 August 2020

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test


0 Comments4 Minutes

14 August 2020

Vaginal ring to reduce the risk of HIV infection for women in non-EU countries with high disease burden


0 Comments4 Minutes

14 August 2020

Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer


0 Comments4 Minutes

24 July 2020

Blenrep (belantamab mafodotin), new option for the treatment of relapsed and refractory multiple myeloma


0 Comments3 Minutes

14 July 2020

Inqovi (decitabine and cedazuridine), new Therapy for Myelodysplastic Syndromes (MDS) That Can Be Taken at Home


0 Comments2 Minutes

7 July 2020

Rukobia (fostemsavir), a new antiretroviral medication for patients who have run out of HIV treatment options


0 Comments3 Minutes

12 June 2020

Uplizna (inebilizumab-cdon)Therapy for Neuromyelitis Optica Spectrum Disorder Offers Patients Additional Treatment Option


0 Comments4 Minutes

6 June 2020

FDA Approves Merck’s RECARBRIO (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)


0 Comments3 Minutes

29 May 2020

FDA Approves Oriahnn (an estrogen and progestin combination product consisting of elagolix, estradiol and norethindrone acetate)to Treat Heavy Menstrual Bleeding Associated with Fibroids in Women


0 Comments6 Minutes

19 May 2020

Qinlock (ripretinib) is the First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors


0 Comments4 Minutes

  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13

Warning:

A cybersecurity incident is under investigation. Please be carefull with emails or phone calls that correctly mention your name, role, or current transactions. Elixi’s crisis team is working to limit any harmful impact, as the security of our clients’ and suppliers’ data is Elixi’s top priority. For any clarification, you can contact: DPO@elixi-int.com

Si è verificato un evento di sicurezza informatica in corso di analisi. Vi invitiamo a prestare massima attenzione messaggi di posta elettronica o telefonate che citano correttamente il vostro nome, la funzione o operazioni realmente avvenute. Il crisis team di Elixi sta lavorando per limitare ogni conseguenza dannosa, perchè la sicurezza dei dati dei nostri clienti e dei fornitori è la nostra priorità di Elixi. Per ogni chiarimento potete contattare: DPO@elixi-int.com